Adlai Nortye Ltd. income statement ANL

Annual Quarterly

It recorded a net loss of $51.9 million. Diluted earnings per share were -$0.54.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
Revenue
—
5
Research and development
45
-22.8%
58
Selling, general and administrative
10
—
Operating income
-53
+27.0%
-73
Pretax income
-52
+52.5%
-109
Income tax
—
1
Net income
-52
+52.5%
-109
Basic EPS
-0.54
+78.6%
-2.52
Diluted EPS
-0.54
+78.6%
-2.52
Weighted average shares, basic
96
+121.0%
43
Weighted average shares, diluted
96
+121.0%
43
Other measures
Depreciation and amortization
1
—
EBITDA
-52
—
Interest coverage
-27.23x
-91.72x
Margins
Operating margin
—
-1,451.02%
Pretax margin
—
-2,184.56%
Profit margin
—
-2,184.56%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ANL (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Singapore
Headquarters
Singapore
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1944552
Former names
Adlai Nortye Ltd. (until Aug 19, 2026)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.